Thursday 21 November 2024

The Pharma Letter Podcast — Episode 23 — AAIC preview with Eisai deputy CCO Michael Irizarry

Biotechnology
Simon Wentworth
6 July 2023
podcast-23-large

More on this story...

Biotechnology
Novel drug launches will lift global Alzheimer's disease market $13.7 billion in 2030
8 June 2023
Pharmaceutical
Otsuka tees up Japanese filing for brexpiprazole in Alzheimer's agitation
28 June 2023
Biotechnology
The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's
17 July 2023
Pharmaceutical
BRIEF—Eisai divest two drugs to Kaken
29 March 2024


Companies featured in this story

More ones to watch >


Today's issue

EC approval for Pfizer’s Hympavzi
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Pharmaceutical
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Biosimilars
Xbrane and Intas to jointly develop Opdivo biosimilar
20 November 2024
Pharmaceutical
Chris Boshoff takes on new role at Pfizer
20 November 2024
Biotechnology
Two Neds better than one in Jupiter’s world of moons
20 November 2024
Pharmaceutical
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Biotechnology

EC approval for Pfizer’s Hympavzi
20 November 2024
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Two Neds better than one in Jupiter’s world of moons
20 November 2024
JAK inhibitors redefining atopic dermatitis treatment
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze